Literature DB >> 18355387

Patient-specific dose finding based on bivariate outcomes and covariates.

Peter F Thall1, Hoang Q Nguyen, Elihu H Estey.   

Abstract

SUMMARY: A Bayesian sequential dose-finding procedure based on bivariate (efficacy, toxicity) outcomes that accounts for patient covariates and dose-covariate interactions is presented. Historical data are used to obtain an informative prior on covariate main effects, with uninformative priors assumed for all dose effect parameters. Elicited limits on the probabilities of efficacy and toxicity for each of a representative set of covariate vectors are used to construct bounding functions that determine the acceptability of each dose for each patient. Elicited outcome probability pairs that are equally desirable for a reference patient are used to define two different posterior criteria, either of which may be used to select an optimal covariate-specific dose for each patient. Because the dose selection criteria are covariate specific, different patients may receive different doses at the same point in the trial, and the set of eligible patients may change adaptively during the trial. The method is illustrated by a dose-finding trial in acute leukemia, including a simulation study.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18355387     DOI: 10.1111/j.1541-0420.2008.01009.x

Source DB:  PubMed          Journal:  Biometrics        ISSN: 0006-341X            Impact factor:   2.571


  22 in total

1.  Do commonly used clinical trial designs reflect clinical reality?

Authors:  Elihu Estey
Journal:  Haematologica       Date:  2009-10       Impact factor: 9.941

2.  Innovative Clinical Trial Designs: Toward a 21st-Century Health Care System.

Authors:  Tze L Lai; Philip W Lavori
Journal:  Stat Biosci       Date:  2011-12

3.  Optimizing natural killer cell doses for heterogeneous cancer patients on the basis of multiple event times.

Authors:  Juhee Lee; Peter F Thall; Katy Rezvani
Journal:  J R Stat Soc Ser C Appl Stat       Date:  2018-03-15       Impact factor: 1.864

Review 4.  Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel.

Authors:  Hartmut Döhner; Elihu Estey; David Grimwade; Sergio Amadori; Frederick R Appelbaum; Thomas Büchner; Hervé Dombret; Benjamin L Ebert; Pierre Fenaux; Richard A Larson; Ross L Levine; Francesco Lo-Coco; Tomoki Naoe; Dietger Niederwieser; Gert J Ossenkoppele; Miguel Sanz; Jorge Sierra; Martin S Tallman; Hwei-Fang Tien; Andrew H Wei; Bob Löwenberg; Clara D Bloomfield
Journal:  Blood       Date:  2016-11-28       Impact factor: 22.113

5.  Phase I/II study of the hypoxia-activated prodrug PR104 in refractory/relapsed acute myeloid leukemia and acute lymphoblastic leukemia.

Authors:  Marina Konopleva; Peter F Thall; Cecilia Arana Yi; Gautam Borthakur; Andrew Coveler; Carlos Bueso-Ramos; Juliana Benito; Sergej Konoplev; Yongchuan Gu; Farhad Ravandi; Elias Jabbour; Stefan Faderl; Deborah Thomas; Jorge Cortes; Tapan Kadia; Steven Kornblau; Naval Daver; Naveen Pemmaraju; Hoang Q Nguyen; Jennie Feliu; Hongbo Lu; Caimiao Wei; William R Wilson; Teresa J Melink; John C Gutheil; Michael Andreeff; Elihu H Estey; Hagop Kantarjian
Journal:  Haematologica       Date:  2015-02-14       Impact factor: 9.941

6.  Bayesian Models and Decision Algorithms for Complex Early Phase Clinical Trials.

Authors:  Peter F Thall
Journal:  Stat Sci       Date:  2010-05       Impact factor: 2.901

7.  A Phase I/II adaptive design for heterogeneous groups with application to a stereotactic body radiation therapy trial.

Authors:  Nolan A Wages; Paul W Read; Gina R Petroni
Journal:  Pharm Stat       Date:  2015-05-11       Impact factor: 1.894

8.  Learning Optimal Personalized Treatment Rules in Consideration of Benefit and Risk: with an Application to Treating Type 2 Diabetes Patients with Insulin Therapies.

Authors:  Yuanjia Wang; Haoda Fu; Donglin Zeng
Journal:  J Am Stat Assoc       Date:  2017-03-31       Impact factor: 5.033

9.  Designs for phase I trials in ordered groups.

Authors:  Mark R Conaway; Nolan A Wages
Journal:  Stat Med       Date:  2016-09-14       Impact factor: 2.373

10.  A new approach to designing phase I-II cancer trials for cytotoxic chemotherapies.

Authors:  Jay Bartroff; Tze Leung Lai; Balasubramanian Narasimhan
Journal:  Stat Med       Date:  2014-02-27       Impact factor: 2.373

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.